...
首页> 外文期刊>Clinical and vaccine immunology: CVI >Novel Catanionic Surfactant Vesicle Vaccines Protect against Francisella tularensis LVS and Confer Significant Partial Protection against F. tularensis Schu S4 Strain
【24h】

Novel Catanionic Surfactant Vesicle Vaccines Protect against Francisella tularensis LVS and Confer Significant Partial Protection against F. tularensis Schu S4 Strain

机译:新型阳离子表面活性剂囊泡疫苗可预防土拉弗朗西斯菌LVS并提供对F. tularensis Schu S4菌株的重要部分保护

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Francisella tularensis is a Gram-negative immune-evasive coccobacillus that causes tularemia in humans and animals. A safe and efficacious vaccine that is protective against multiple F. tularensis strains has yet to be developed. In this study, we tested a novel vaccine approach using artificial pathogens, synthetic nanoparticles made from catanionic surfactant vesicles that are functionalized by the incorporation of either F. tularensis type B live vaccine strain (F. tularensis LVS [LVS-V]) or F. tularensis type A Schu S4 strain (F. tularensis Schu S4 [Schu S4-V]) components. The immunization of C57BL/6 mice with “bare” vesicles, which did not express F. tularensis components, partially protected against F. tularensis LVS, presumably through activation of the innate immune response, and yet it failed to protect against the F. tularensis Schu S4 strain. In contrast, immunization with LVS-V fully protected mice against intraperitoneal (i.p.) F. tularensis LVS challenge, while immunization of mice with either LVS-V or Schu S4-V partially protected C57BL/6 mice against an intranasal (i.n.) F. tularensis Schu S4 challenge and significantly increased the mean time to death for nonsurvivors, particularly following the i.n. and heterologous (i.e., i.p./i.n.) routes of immunization. LVS-V immunization, but not immunization with empty vesicles, elicited high levels of IgG against nonlipopolysaccharide (non-LPS) epitopes that were increased after F. tularensis LVS challenge and significantly increased early cytokine production. Antisera from LVS-V-immunized mice conferred passive protection against challenge with F. tularensis LVS. Together, these data indicate that functionalized catanionic surfactant vesicles represent an important and novel tool for the development of a safe and effective F. tularensis subunit vaccine and may be applicable for use with other pathogens.
机译:图拉弗朗西斯菌是一种革兰氏阴性免疫逃逸球菌,可导致人和动物的图拉菌血症。尚未开发出一种安全有效的疫苗,该疫苗可对抗多种土拉弗朗西斯菌。在这项研究中,我们测试了一种使用人工病原体,由阳离子表面活性剂囊泡制成的合成纳米颗粒的新型疫苗方法,该表面活性剂通过掺入土拉弗朗西斯菌B型活疫苗菌株(F. tularensis LVS [LVS-V])或F tularensis A型Schu S4菌株(F. tularensis Schu S4 [Schu S4-V])组件。 C57BL / 6小鼠用“裸露”囊泡进行免疫,这种裸露囊泡不表达tularensis组分,部分保护了tularensis FVS,这可能是通过先天免疫应答的激活而实现的,但它未能保护tularensis F. Schu S4株。相反,用LVS-V免疫可完全保护小鼠免受腹膜内(ip)tularensis LVS攻击,而用LVS-V或Schu S4-V免疫小鼠可部分保护C57BL / 6小鼠免于鼻内(in)F。 tularensis Schu S4攻击并显着增加了非幸存者的平均死亡时间,尤其是在和异源(即i.p./i.n。)免疫途径。 LVS-V免疫(但未用空囊泡免疫)引发高水平的针对非脂多糖(non-LPS)表位的IgG,在T.tularensis LVS攻击后该表位增加,并显着增加了早期细胞因子的产生。来自LVS-V免疫小鼠的抗血清赋予被动防御以抵抗土拉弗朗西斯菌LVS的攻击。总之,这些数据表明功能化的阳离子表面活性剂囊泡代表了开发安全有效的土拉弗朗西斯菌亚单位疫苗的重要且新颖的工具,并且可能适用于与其他病原体一起使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号